IDOX trades in line following 'strong progress' in H1

IDOX said interim revenues were expected to grow 13% to £35.1m, while adjusted underlying earnings were projected to have surged 138% to £9.6m as EBITDA margins improved 27% year-on-year.

The AIM-listed group also said it continued to improve sales governance and execution, margin enhancement, communication and organisation simplicity.

As far as the Covid-19 pandemic was concerned, IDOX said its full-year financial performance was expected to be in line with existing expectations and highlighted the fact that it had not needed to participate in any government job retention schemes.

Chief executive David Meaden said: "The group has successfully risen to the challenges caused by the Covid-19 pandemic. Our core business model of home working and focus on the public sector means Idox is well placed to deal with the unfolding impacts of Covid-19.

"We continue to manage the exposures in the business, and support our customers, employees and wider communities. Consequently, we remain cautiously optimistic about the future."

As of 1350 BST, IDOX shares were up 4.74% at 42.21p.